BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cobenfy (Xanomeline/trospium chloride) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cobenfy (Xanomeline/trospium chloride)\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06585787-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20261124
DTEND;VALUE=DATE:20261125
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 585787)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Evaluate KarXT as a Treatment for Psychosis As
 sociated With Alzheimer's Disease (ADEPT-4)\nEstimated primary completion:
  24 November 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/xa
 nomeline-trospium-chloride#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06585787
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07681076-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 4 readout est. (NCT07
 681076)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 4.\nStudy: Study
  to Assess Safety and Tolerability of KarXT With Administration of Antieme
 tics in Healthy Volunteers\nEstimated primary completion: 30 November 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/xanomeline-trospium
 -chloride#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07681076
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06126224-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20261209
DTEND;VALUE=DATE:20261210
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 126224)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Assess Efficacy and Safety of KarXT for the Tr
 eatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)\nEstima
 ted primary completion: 9 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06126224
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07063342-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20270329
DTEND;VALUE=DATE:20270330
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 1 readout est. (NCT07
 063342)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 1.\nStudy: A Stu
 dy to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC
  Reference Following Single Doses\, Explore the Effect of Food After Multi
 ple Doses of Selected Prototypes\, and Evaluate Alternative Formulations o
 f KarX and KarXT Following Single and Multiple Ascending Doses\nEstimated 
 primary completion: 29 March 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07063342
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07423546-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 1/2 readout est. (NCT
 07423546)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 1/2\, Schizophre
 nia.\nStudy: A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizo
 phrenia\nEstimated primary completion: 30 April 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07423546
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07061288-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20270621
DTEND;VALUE=DATE:20270622
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 1 readout est. (NCT07
 061288)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 1\, Schizophreni
 a.\nStudy: A Study to Evaluate the Safety\, Tolerability\, and PK of an In
 jectable Form of KarXT\nEstimated primary completion: 21 June 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/xanomeline-trospium-chlorid
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 061288
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07140913-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20270628
DTEND;VALUE=DATE:20270629
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 140913)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Bipolar Diso
 rder.\nStudy: A Study to Evaluate the Efficacy and Safety of Adjunctive Ka
 rXT for the Treatment of Mania\, With or Without Mixed Features\, in Parti
 cipants With Bipolar-I Disorder Taking Lithium\, Valproate\, or Lamotrigin
 e\nEstimated primary completion: 28 June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07140913
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05980949-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20270907
DTEND;VALUE=DATE:20270908
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT05
 980949)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: Open-Label Extension Study to Assess the Long-Term Safety
  and Tolerability of KarXT in Subjects With Psychosis Associated With Alzh
 eimer's Disease (ADEPT-3)\nEstimated primary completion: 7 September 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/xanomeline-trospium-
 chloride#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05980949
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221877-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 4 readout est. (NCT07
 221877)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 4\, Schizophreni
 a.\nStudy: A Study to Evaluate the Effect of KarXT on Urological Safety\nE
 stimated primary completion: 30 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07221877
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06947941-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20280221
DTEND;VALUE=DATE:20280222
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 947941)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Evaluate Safety and Efficacy of KarXT + KarX-E
 C as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-
 5)\nEstimated primary completion: 21 February 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06947941
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06929273-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20280613
DTEND;VALUE=DATE:20280614
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 929273)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Bipolar Diso
 rder.\nStudy: A Study to Assess the Long-term Safety of KarXT for the Trea
 tment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)\nEstimated primar
 y completion: 13 June 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06929273
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976216-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20280911
DTEND;VALUE=DATE:20280912
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 976216)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Evaluate the Efficacy and Safety of KarXT + Ka
 rX-EC for Cognitive Impairment in Alzheimer's Disease\nEstimated primary c
 ompletion: 11 September 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06976216
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976203-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20280911
DTEND;VALUE=DATE:20280912
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 976203)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Evaluate the Efficacy and Safety of KarXT + Ka
 rX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)\nEstimat
 ed primary completion: 11 September 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06976203
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06882785-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20280923
DTEND;VALUE=DATE:20280924
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 882785)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Schizophreni
 a.\nStudy: A Study to Evaluate the Efficacy and Safety of KarXT in Acutely
  Psychotic Japanese Adult Participants With Schizophrenia\nEstimated prima
 ry completion: 23 September 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06882785
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011745-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20281103
DTEND;VALUE=DATE:20281104
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 011745)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Phase 3 Study to Evaluate the Safety and Efficacy of Ka
 rXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's D
 isease\nEstimated primary completion: 3 November 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07011745
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011732-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20281124
DTEND;VALUE=DATE:20281125
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 011732)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Phase 3 Study to Evaluate the Safety and Efficacy of Ka
 rXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's D
 isease (ADAGIO-1)\nEstimated primary completion: 24 November 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/xanomeline-trospium-chloride
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 11732
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686263-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20290303
DTEND;VALUE=DATE:20290304
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 686263)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Schizophreni
 a.\nStudy: Relapse Prevention Trial Evaluating KarXT Treatment in Schizoph
 renia\nEstimated primary completion: 3 March 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07686263
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06937229-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20290622
DTEND;VALUE=DATE:20290623
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 937229)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Evaluate the Long-term Efficacy and Safety of 
 KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)\nEstimated
  primary completion: 22 June 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06937229
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284745-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20290806
DTEND;VALUE=DATE:20290807
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 284745)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3.\nStudy: A Stu
 dy of KarXT + KarX-EC for Treatment of Irritability in Children and Adoles
 cents With Autism\nEstimated primary completion: 6 August 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/xanomeline-trospium-chloride#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072847
 45
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285798-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20290806
DTEND;VALUE=DATE:20290807
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 285798)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3.\nStudy: A Stu
 dy of KarXT + KarX-EC for Treatment of Irritability in Children and Adoles
 cents With Autism Spectrum Disorder\nEstimated primary completion: 6 Augus
 t 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/xanomeline-tr
 ospium-chloride#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07285798
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288567-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 288567)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Schizophreni
 a.\nStudy: A Study to Evaluate the Efficacy and Safety of KarXT for the Tr
 eatment of Schizophrenia in Adolescents (EMERGENT TEEN)\nEstimated primary
  completion: 18 December 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07288567
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07424404-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20300308
DTEND;VALUE=DATE:20300309
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 424404)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Schizophreni
 a.\nStudy: A Study to Evaluate the Long-term Safety and Tolerability of Xa
 nomeline and Trospium Chloride for the Treatment of Psychiatric Disorders 
 in Children and Adolescents\nEstimated primary completion: 8 March 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/xanomeline-trospium-ch
 loride#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07424404
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07721272-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 1 readout est. (NCT07
 721272)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 1.\nStudy: Human
  Cognition During Surgery: Stimulation-based and Cholinergic Modulation\nE
 stimated primary completion: September 2030. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07721272
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07228338-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 1 readout est. (NCT07
 228338)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 1.\nStudy: Choli
 nergic Enhancement of Theta\nEstimated primary completion: December 2031. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/xanomeline-trospium-c
 hloride#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07228338
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624227-712@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 1/2 readout est. (NCT
 07624227)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 1/2.\nStudy: The
  Impact of Cobenfy Maintenance on Cocaine's Effects\nEstimated primary com
 pletion: 30 June 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/xanomeline-trospium-chloride#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07624227
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
